Arca
Skip to content

Sickle cell disease

Drug research and approvals for sickle cell disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 166 studies of sickle cell disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 34 drug trials for it since 2013, FDA has 8 approved and 61 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 166
  • Trials authorized in Canada: 34
  • FDA orphan approvals: 8
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 166 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 34; search them all in Canada trials
Sep 4, 2026A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the effect of mitapivat on transfusion burden in subjects with sickle…MITAPIVAT (AG-348)Agios PharmaceuticalsPending
Feb 4, 2026Phase 2a, multicenter, randomized, doubleblind, placebo-controlled study to assess the safety of anumigilimab (csl324) in adults with sickle cell diseaseCSL324 (ANUMIGILIMAB)CSLClosed
Dec 9, 2025A phase 2/3 randomized, multicenter study of osivelotor administered orally to adult and adolescent participants with sickle cell diseaseOSIVELOTOR (PF-07940367, GBT021601)PfizerPending
Sep 24, 2025A multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to determine efficacy and safety of sil-8301 in sickle cell…SENICAPOC (SIL-8301)BIOSSIL INC.Ongoing
Apr 14, 2025A phase 2, double-blind, randomized, placebo-controlled, multicenter, dose-finding, efficacy, and safety study of tebapivat in participants with sickle cell…TEBAPIVAT (AG-946)Agios PharmaceuticalsOngoing
Dec 6, 2024A phase 2 / phase 3, multicenter, randomized, multiple-dose, double-blind, placebo-controlled adaptive study to evaluate the safety, efficacy, and…CSL889CSLPending
Jul 31, 2024An open-label mechanistic study to assess the pharmacokinetics, pharmacodynamics and safety of orally administered epeleuton in patients with sickle cell…EPELEUTON (DS102)AFIMMUNE LIMITEDClosed
Dec 29, 2022An open-label extension study to evaluate the long-term safety of gbt021601 administered to participants with sickle cell disease who have participated in a…GBT021601PfizerClosed
Nov 2, 2022A phase 2a, randomized, open-label study to evaluate multiple dosing regimens of subcutaneous alxn1820 in adult patients with sickle cell diseaseALXN1820AstraZeneca Pharmaceuticals LPOngoing
Aug 5, 2022A 2-part, phase 1, multicenter, single-dose, open-label study to evaluate the safety, tolerability, and pharmacokinetics of csl889 in adult patients with…CSL889CSLPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 69
Jul 1, 2026Casgevytreatment of patients aged 2 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crisesVertex Pharmaceuticals Inc.Approved
Dec 8, 2023Casgevytreatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs)Vertex Pharmaceuticals Inc.Approved
Dec 8, 2023Lyfgeniatreatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive eventsGenetix Biotherapeutics Inc.Approved
Dec 17, 2021Oxbrytatreatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and olderGlobal Blood Therapeutics, Inc.Approved
Nov 25, 2019OxbrytaOXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.Global Blood Therapeutics, Inc.Approved
Nov 15, 2019ADAKVEOADAKVEO® is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with…Novartis Pharmaceuticals CorporationApproved
Dec 21, 2017SiklosTo reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older,…Theravia PharmaApproved
Jul 7, 2017EndariTo reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.Emmaus Medical, Inc.Approved
Oct 6, 2026small-molecule activator of nuclear factor erythroid…treatment of sickle cell diseasevTv Therapeutics LLCDesignated
Feb 19, 2026tebapivattreatment of sickle cell diseaseAgios Pharmaceuticals, Inc.Designated
Feb 4, 2026desidustatTreatment of Sickle Cell DiseaseZydus Healthcare (USA), LLC,Designated
Jun 23, 2025fetal hemoglobin activator cereblon (CRBN) E3…treatment of sickle cell diseaseBristol-Myers SquibbDesignated
Jun 9, 2025(lE, 6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-…treatment of sickle cell diseaseVascarta Inc.Designated
May 30, 2025autologous CD34+ cell therapy comprised of hematopoietic…treatment of sickle cell diseaseBeam TherapeuticsDesignated
May 15, 2025rilzabrutinibtreatment of sickle cell disease (SCD)Sanofi US Services Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jul 1, 2019XromihydroxycarbamideLipomed GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.